Expand DRTS Menu
DRTS MENU

DRTS Latest Press Releases

-- September 2, 2026 --

Alpha Tau to Participate in September Investor Conferences Globe Newswire 8:00 AM

-- August 31, 2026 --

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT Following Strong Demand and Multiple Expansions Globe Newswire 8:00 AM

-- August 17, 2026 --

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee Globe Newswire 8:00 AM

-- August 10, 2026 --

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) Globe Newswire 8:00 AM

-- July 21, 2026 --

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success Globe Newswire 8:30 AM

-- July 15, 2026 --

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center Globe Newswire 8:30 AM

-- June 25, 2026 --

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet PRNewswire 11:35 AM

-- June 23, 2026 --

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel Globe Newswire 8:30 AM

-- June 11, 2026 --

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control Globe Newswire 8:30 AM

-- June 3, 2026 --

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients Globe Newswire 8:30 AM

-- June 1, 2026 --

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting Globe Newswire 9:00 AM

-- May 18, 2026 --

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM
Alpha Tau to Participate in May Investor Conferences Globe Newswire 8:30 AM

-- May 11, 2026 --

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET Globe Newswire 7:00 AM

-- May 8, 2026 --

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma Globe Newswire 9:10 AM
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT to Treat Recurrent Cutaneous Squamous Cell Carcinoma Globe Newswire 9:00 AM

-- May 7, 2026 --

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT at the University of Verona's Pancreas Institute Globe Newswire 9:00 AM

-- May 5, 2026 --

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT Head and Neck Cancer Combination with Pembrolizumab Globe Newswire 9:14 AM

-- May 4, 2026 --

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026 Globe Newswire 9:17 AM

-- April 27, 2026 --

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies Globe Newswire 9:01 AM

-- April 23, 2026 --

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane (Nab-Paclitaxel) Globe Newswire 9:02 AM
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT in French Multicenter ACAPELLA Clinical Trial Globe Newswire 9:01 AM
Market Data Delayed 15 Minutes